In the news
Cost-benefit analysis set for Advate, hemophilia A treatment
December 21, 2020Hemophilia News Today
Related news
In the news
May 29, 2022
Biosimilars Can Help Lower Patient Drug Costs When the Right Teams Come Together: Prime Therapeutics Executive
Managed Healthcare Executive
In the news
May 5, 2022
Prime Therapeutics buying Magellan Health’s pharma business for $1.35 billion
Minneapolis/St. Paul Business Journal